Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Dysphagia in Prader-Willi Syndrome
NCT05298085Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 3 trial of oxytocin nasal spray in Prader-Willi syndrome (PWS), sponsored by Centre hospitalier universitaire de Toulouse. Started Apr 2022; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT05298085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298085.